IVY RX Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A medication name, a laboratory-testing claim and a low starting price answer different questions. IVY RX brings all three together in its marketing for compounded GLP-1 weight-loss treatment. For a prospective patient, the central evidence question is not simply whether semaglutide or tirzepatide has been studied. It is whether the company documents the particular preparation, service and financial arrangement being offered—and how far research on other products can reasonably inform that decision.

Public documentation consulted October 19, 2026, establishes that IVY RX advertises online assessment, clinician review, partner-pharmacy fulfillment, free delivery and ongoing subscriptions. It does not establish outcomes for IVY RX patients or settle every operational detail. This review separates documented offerings from provider assertions and independent clinical context. The result is a service with recognizable access pathways, but important unanswered questions about the final prescription, pharmacy identity, total price, follow-up and refund handling.

At a glance

Documented prescription offering: IVY RX advertises compounded semaglutide and tirzepatide; prescriptions depend on a healthcare-provider consultation and approval.
Sources: [7]
Advertised starting prices: GLP-1 medication starts at $77 and microdose GLP-1 starts at $69, each labeled “4 doses/month”; the documentation does not establish a complete price for every option.
Sources: [7] [5]
Recurring payment structure: Terms describe self-pay subscriptions, either one month prepaid or three months prepaid, followed by monthly automatic renewal.
Sources: [9]
Quality-testing claims: IVY RX advertises state-licensed pharmacy preparation, laboratory verification, sterility screening and potency testing every three to six months; these claims were not independently verified here.
Sources: [7]
Evidence boundary: Compounded preparations are not FDA approved. FDA recommends them when an individual's medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy.
Sources: [1]

Start with the product, not the shared ingredient name

IVY RX explicitly lists compounded semaglutide and tirzepatide, including a separate compounded microdose offering. Its broader menu also links GLP-1 injections, GLP-1 Oral Melts, Ozempic, Mounjaro, metformin, anti-nausea tablets and MIC + B12 injections. That catalog is evidence of advertised categories, not confirmation that every listed product is available to every patient. It also does not establish the prescription criteria, presentation or price attached to each entry.

That distinction matters because the website's starting-price cards do not identify a complete, universally applicable formulation-and-payment combination. Someone comparing options needs the actual prescription name, route, presentation and dispensing pharmacy—not merely the heading “GLP-1.” The distinction is especially important when moving between injections, oral products and microdose marketing. Our guide to formulation and route differences explains why a shared ingredient name does not settle the evidence question.

The catalog extends beyond prescription GLP-1 treatment. GLP-1 Boost is advertised as a supplement starting at $72 for 30 tablets, and its FAQ explicitly says it contains neither GLP-1 nor synthetic peptides. Its safety information acknowledges limited robust human data on the exact combination and says it is not a substitute for prescribed medication. The documented listing also contains tablet-versus-capsule language and an incongruous injection-testing reference, making product-specific clarification particularly useful.

Different advertised offerings require different evidence checks
Offering	What IVY RX documents	What remains to confirm
Compounded GLP-1	Semaglutide or tirzepatide; from $77; “4 doses/month”	Specific medicine, presentation and complete charge
Compounded microdose GLP-1	Semaglutide or tirzepatide; from $69; “4 doses/month”	Exact prescription and applicable payment arrangement
GLP-1 Oral Melts	A linked catalog category	Availability, formulation, prescribing conditions and price
Ozempic and Mounjaro	Named catalog links	Actual availability and product-specific terms
GLP-1 Boost	Supplement from $72 for 30 tablets; no GLP-1 or synthetic peptides	Presentation details and evidence for the exact combination

Sources: [7] [5] [6] [10]

Clinical research does not measure IVY RX's performance

The independent clinical context includes randomized trials of subcutaneous semaglutide and tirzepatide in adults without diabetes who had obesity or overweight with a related condition. Those studies concern specified treatment regimens and trial populations. They are not studies of IVY RX, its compounded preparations, its microdose offering or its oral products. Neither trial supplies a patient-outcome estimate for this service, and their results should not be repurposed as evidence that one telehealth company performs better than another.

FDA explains that compounded preparations are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. That absence of approval does not, by itself, prove clinical inequivalence or establish that a provider is good or bad. FDA recommends compounded drugs for patients whose needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Our explanation of approved and compounded medicines separates these regulatory and evidence questions.

IVY RX itself states that FDA does not review compounded medicines for safety or effectiveness. That disclosure is relevant, but it does not answer whether a particular patient's proposed preparation is appropriate or how that preparation was evaluated. The useful question is what evidence supports the exact product and care plan being offered. As our guide explains, a clinical trial is not a company performance report; ingredient-level research cannot replace provider-specific documentation.

Sources: [3] [4] [1] [7]

What the pharmacy and testing claims actually establish

IVY RX says its treatments are compounded in pharmacies compliant with “503B/USP <797> standards.” It also describes preparation in a state-licensed pharmacy and independent verification in FDA- and DEA-registered laboratories. These are provider assertions in the consulted documentation, not independently verified findings from this review. The material does not name the pharmacies or laboratories that would handle a particular prescription, leaving the reader unable to connect the broad claims to a specific dispenser or testing report.

The product page describes potency checks every three to six months, with results within plus or minus 10% of target strength, and sterility screening for bacteria, fungi and other contaminants. Those details are more informative than an unexplained “quality tested” badge, but they do not establish testing of every individual shipment. Nor does a laboratory's registration mean FDA has approved the compounded preparation. A useful next request is the dispensing pharmacy's identity and the documentation applicable to the prescribed product.

Sources: [7] [1]

Online assessment is documented; eligibility is less clear

The advertised intake is entirely online and asks about symptoms and health history. IVY RX says it arranges a consultation with a qualified healthcare provider and that approved prescriptions can be filled at a partner pharmacy. It advertises same-day physician review, approval notification by email and no required labwork. These statements describe the access process, not guaranteed prescribing. The company also says its affiliated doctors are board certified and US licensed; this review did not independently verify individual credentials.

The terms restrict site and app use to adults 18 or older, or the age of majority in their jurisdiction. Clinical eligibility is a separate matter. The BMI calculator labels values below 22 ineligible, promotes microdose below 24.99 and labels full-dose above 25. Those labels overlap and leave boundary questions unresolved. They should not be read as a complete clinical policy. NIDDK's general adult pharmacotherapy thresholds are 30 or higher, or 27 or higher with weight-related health problems; neither framework establishes an individual's eligibility.

The consulted GLP-1 page also publishes safety exclusions involving medullary thyroid carcinoma history, MEN2, pregnancy, attempts to become pregnant and breastfeeding. Its injection page introduces the safety block as Microdose GLP-1 information, so the exact correspondence between that block and each offering merits clarification. More broadly, NIDDK advises discussing health conditions, other medicines, supplements, allergies and pregnancy plans with the treating clinician. A brief online eligibility label cannot substitute for that individualized review.

Sources: [7] [5] [9] [2]

Starting prices are visible, but the complete bill is not

The standard GLP-1 card advertises “From $77” and the microdose card “From $69,” both with “4 doses/month.” These are starting-price claims, not confirmed all-inclusive monthly quotes for both molecules. The consulted documentation does not map either figure to a particular medicine, presentation or prepayment choice. Four advertised doses also do not establish the quantity in a dispensed container. The missing information includes injection supplies, potential additional charges and the total collected when an actual plan is selected.

The homepage advertises a free consultation and free, discreet delivery, while the GLP-1 page says no insurance is needed. The terms nevertheless establish a self-pay subscription: either one month prepaid with monthly renewal or three months prepaid with monthly renewal. Those are alternatives, not a universal three-month prepayment requirement. The documentation does not tie them to the starting-price cards or establish a specific introductory-versus-renewal price schedule. A written checkout quote is therefore more useful than extrapolating from the headline.

IVY RX's “Same price, every dose” message also needs to be read beside terms reserving the right to increase subscription fees. It is not a demonstrated lifetime price lock. Separately, the company says GLP-1 therapy is HSA/FSA eligible and promises an itemized receipt for reimbursement submission. That is the provider's statement, not confirmation of an individual's reimbursement outcome. No insurance requirement should likewise not be mistaken for an insurance-covered prescription or a verified benefit determination.

Sources: [7] [5] [8] [9]

Delivery promises and follow-up need separate timelines

For GLP-1 orders, IVY RX advertises free delivery in discreet, temperature-controlled packaging. One product-page promotion says medication can arrive in as little as two days; the help center says delivery usually takes three to five business days. These are different claims, not interchangeable guarantees. Neither should be confused with same-day clinical review. The documentation does not settle carrier choice, tracking arrangements, replacement for a lost or damaged package, or the provider's procedure for a temperature-related shipping problem.

FDA explicitly advises not using an injectable GLP-1 drug that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. IVY RX's packaging claim does not override that advice. After delivery, patients can securely message care providers through the portal; the site also advertises live support and a free mobile app. Support is described as available seven days a week, but hours and guaranteed clinician response times are not established.

The public material does not specify a routine clinical follow-up schedule or prescription-renewal requirements. That is a different gap from customer-service availability: portal access shows a communication channel, not how often tolerance and response will be reviewed. NIDDK describes ongoing care as involving both response and side effects. Our guide to clinical follow-up beyond renewal notices can help readers ask who reviews concerns, when reassessment occurs and how clinical responsibility continues after shipment.

Sources: [7] [11] [12] [1] [2]

Cancellation, returns and refunds are different procedures

The subscription automatically renews and charges the card on file. Terms say cancellation must occur before the current subscription period ends to avoid the subsequent month's charge. A billing clause allows cancellation or modification through the patient portal, while another section directs users to support. The weight-loss page advertises no long-term contracts or cancellation fees. Those statements do not erase a prepaid period or establish a right to recover money already paid; cancellation concerns future renewal, not necessarily reimbursement.

The separate refund policy says physical returns are not accepted and invites customers to contact the company about problems. The terms describe a different route: a dissatisfied customer may request a refund within 15 days of the order by emailing info@ivyrx.com with “Refund Request” as the subject. After that period, the terms describe sales as final and ineligible for refund. A request is not guaranteed approval, and the documentation does not clarify application to prescribed or already-shipped products.

Sources: [9] [6] [12]

Identify the responsible entities before enrolling

The terms name Ivy Rx, PLLC as the agreement's counterparty, while the consulted material also shows Ivy Health Inc. in the terms footer without explaining the relationship. Public contact information includes 866-464-8979, hello@ivyrx.com and 111 NE 1st Street, 8th Floor #8564, Miami, FL 33132. That address does not establish an in-person clinic. The refund-policy support address is support@ivyrx.com, distinct from the terms' designated refund-request address.

Several practical boundaries remain undocumented: states served, geographic prescribing and shipping restrictions, the clinician assigned to a case, the dispensing pharmacy, video-visit availability and language-access arrangements. Missing documentation is not proof these services or arrangements do not exist. It means a prospective patient cannot confirm them from the consulted pages. Before payment, the most productive evidence request is a written account of who prescribes, who dispenses, what is charged, and who handles clinical or delivery problems.

Sources: [9] [8] [12]

Questions & answers

Does IVY RX's $77 advertisement establish my monthly treatment cost?

No. It is a “From” price labeled “4 doses/month,” not a complete quote for every compounded semaglutide or tirzepatide option. The microdose card similarly starts at $69. Ask which medicine and presentation the quote covers, what is collected initially, which prepayment option applies, and what the next renewal will cost.

Sources: [7] [5] [9]

Are IVY RX's compounded preparations FDA approved?

No. Compounded preparations are not FDA approved, and IVY RX acknowledges that FDA does not review them for safety or effectiveness. This status alone does not prove clinical inequivalence. FDA recommends compounded drugs when an individual's needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy.

Sources: [7] [1]

Does IVY RX identify the pharmacy that would fill my prescription?

The consulted pages describe partner pharmacies, state licensing and quality standards, but do not identify the pharmacy assigned to an individual order. Request that identity before proceeding, along with product-specific documentation. Claims about laboratory verification and sterility testing are not independent verification by this review or FDA approval of the preparation.

Sources: [7]

Does a same-day review mean same-day approval or delivery?

No. IVY RX advertises same-day physician review and emailed approval notification, but prescribing depends on the consultation. Its fastest advertised arrival is “as little as” two days; the help center describes three to five business days in most cases. None of those statements guarantees a particular person's approval or delivery date.

Sources: [7] [11]

Will canceling IVY RX automatically produce a refund?

The documentation does not promise that. Cancellation before the current period ends avoids the next monthly renewal under the terms. Refund requests have a separate 15-day-from-order window and designated email procedure, while physical returns are not accepted. Whether a request involving prescribed or shipped medication will be approved remains unclear.

Sources: [9] [12]

Is GLP-1 Boost the same as IVY RX's prescription treatment?

No. IVY RX labels Boost a supplement and says it contains no GLP-1 or synthetic peptides. It starts at $72 for an advertised 30 tablets. The company acknowledges limited robust human evidence for the exact combination and says it does not replace prescribed medication. Prescription-drug trial results should not be treated as evidence for this supplement.

Sources: [10] [3] [4]

Our assessment

IVY RX documents a real advertised telehealth pathway: online intake, conditional prescribing, partner-pharmacy fulfillment, delivery and portal communication. It also provides more detail about claimed testing than a simple quality badge. The limitations are substantial, however: these claims were not independently verified, clinical trials do not establish outcomes for its preparations, and the public material leaves the final price, assigned pharmacy, follow-up schedule and some refund applications unresolved. Its starting prices are useful comparison points only after the actual prescription and recurring payment terms are confirmed. A reasonable documentary next step is to obtain those particulars in writing, rather than treating ingredient names, speed claims or laboratory language as a complete account of care.

Visit IVY RX’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

IVY RX Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the product, not the shared ingredient name

02Clinical research does not measure IVY RX's performance

03What the pharmacy and testing claims actually establish

04Online assessment is documented; eligibility is less clear

05Starting prices are visible, but the complete bill is not

06Delivery promises and follow-up need separate timelines

07Cancellation, returns and refunds are different procedures

08Identify the responsible entities before enrolling